Dr. Amit Kumar Pandey - National Institute of Pharmaceutical Education & Research, Ahmedabad

Dr. Amit Kumar Pandey, Ph.D.

Identifying novel lncRNA-mediated molecular pathways to discover potential biomarkers and therapeutic targets for aggressive cancers.
Investigating how lncRNAs influence tumor onset, development, and progression.
Deciphering the complex interactions and regulatory mechanisms between the p53 tumor suppressor pathway and lncRNAs in ovarian cancer.

May 2023- Present
Associate Professor
NIPER-Ahmedabad, Palaj, Gandhinagar, Gujarat
March 2018- May 2023
Assistant Professor
Amity Institute of Biotechnology, Amity University Haryana, Haryana
March 2013- March 2018
Research Fellow
Cancer Science Institute, National University of Singapore, Singapore
June 2012- Jan 2013
Postdoc fellow
Max Delbruck Center for Molecular medicine, Berlin, Germany
June 2009- July 2012
Senior Research Fellow, CSIR
Institute of Genomics and Integrative Biology, Delhi , India

Gujarat State Biotechnology Mission (GSBTM), DST, Gov. of Gujarat
Indian Council of Medical Research (ICMR), Investigating of the role of LncRNA PANDAR in the progression and metastasis of ovarian cancer (2022-2024)
GSBTM funded project titled “Design and evaluation of formulation for management of cutaneous complications induced by chemotherapeutics: A gentle touch in the face of adversity” (2026-2028)
DST-RSF, Indo-Russia International Collaboration Research Grant, Unraveling the molecular mechanism of lncRNAs involvement in Glioblastoma (2019-2022)
Early Career Research Award–DST-SERB, Understanding Wnt Pathway and LncRNAs interaction for the identification of novel therapeutic targets in triple-negative breast cancers (2019-2022)
Indian Council of Medical Research (ICMR), Identifying the role of P53 regulated long non-coding RNAs (LncRNAs) by Crispr/Cas9 in ovarian cancer (2019-2022)
Indian Council of Medical Research (ICMR), Senior Research Fellowship Samarth Kansara (Student), Elucidating the role of Wnt regulated lncRNA Linc00645 in the pathogenesis of Triple-Negative Breast Cancer as a key therapeutic target (2022-2024)
Indian Council of Medical Research (ICMR), Senior Research Fellowship 2022 – Abhisesh Kumar Badal (Student), Identification of p53 mediated LINC01021 lncRNA and use as a potential therapeutic (Biomarker) / diagnostic tool in Ovarian cancer (2022-2024)

Tip 60-Mir 22 Axis as A Biomarker of Breast Cancer Progression and Methods of Treatment of Breast Cancer.
Inventors: Sudhakar Jha and Amit Kumar Pandey.
US Provisional Patent Application No. 62/208,071
Process for the Synthesis of Substituted C8-Oxygenated Indolizines and Therapeutic Applications Thereof, in process of filing.
Satyasheel Sharma, Amit Kumar Pandey, Karthikeyan Rajkumar, Vinita Sudhakar Jagtap,
Application No. 9939IN036